20-06-2019
Phushutter / Shutterstock.com
US pharmaceutical company Amphastar Pharmaceuticals is to receive $59.9 million in a settlement agreement with two of its competitors, Sandoz and Momenta Pharmaceuticals.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Amphastar Pharmaceuticals, Momenta Pharmaceuticals, Sandoz, settlement, patent infringement, patent validity, blood thinner
Sanofi-Aventis gets $17.2m in fees from failed Amphastar suit
06-05-2021
Judge approves $120m Momenta and Sandoz settlement
06-01-2020
Adamas settles Gocovri clash with Sandoz
03-01-2020
Momenta to pay $35m to end enoxaparin class-action suit
12-12-2019
Jury sides with Amphastar in patent case against Momenta
24-07-2017
